Patient Derived Xenograft (PDX) Model Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global Patient Derived Xenograft (PDX) Model Market size was estimated at USD 573 million in 2024 and is projected to reach USD 1,599.98 million in 2031 at a CAGR of 15.8 % during the forecast period 2025-2031.

The Patient Derived Xenograft (PDX) model market revolves around the use of tumor tissues directly taken from cancer patients and implanted into immunodeficient mice for preclinical research. These models retain the genetic, histological, and behavioral characteristics of the original human tumors, offering a more accurate representation of how cancers respond to therapies compared to traditional cell line models. As precision medicine and targeted cancer treatments gain ground, PDX models have become an essential tool for translational oncology research and drug development.

The scope of the PDX model market covers pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic research institutions. It supports applications in oncology drug development, biomarker discovery, treatment response studies, and personalized medicine. The market also includes associated services such as tumor implantation, model expansion, and genetic characterization. With increasing cancer incidence globally, there is a growing demand for more predictive and clinically relevant models that can reduce failure rates in clinical trials.

Key trends in the PDX model market include the integration of humanized mouse models to mimic the human immune system for immuno-oncology research, advancements in genomics and molecular profiling, and increased collaboration between industry and academia. The development of PDX biobanks and databases is streamlining access to diverse tumor types and enhancing reproducibility in research. Moreover, innovations in 3D modeling and in vivo imaging are improving the monitoring and analysis of tumor behavior in these models.

The primary drivers of the market include the rising global cancer burden, growing investment in oncology R&D, and the need for more predictive preclinical models to improve drug development success rates. Regulatory pressure to use more accurate models and the trend toward personalized medicine also contribute to market growth. As pharmaceutical companies aim to de-risk clinical trials, the demand for PDX models that better reflect human tumor biology is expected to rise, solidifying their role in next-generation cancer research and therapy development.

Impacts USA tariff rates on the Patient Derived Xenograft (PDX) Model Market

The imposition of pharmaceutical tariffs by the Trump administration in 2025 has introduced significant challenges to the Patient-Derived Xenograft (PDX) model market. These tariffs, targeting pharmaceutical imports, have led to increased costs and potential supply disruptions in the U.S. healthcare sector. Generic drug producers, operating on tight margins, are particularly affected, with some considering market exits due to unviable cost structures. Given that PDX models rely on a complex supply chain involving human tumor tissues and specialized reagents, these tariffs have exacerbated existing logistical challenges, potentially delaying research and development activities. Moreover, the increased operational costs may deter smaller biotech firms and academic institutions from engaging in PDX-based research, thereby slowing the pace of innovation in personalized medicine.

Delvens Industry Expert's Standpoint

Experts in the Patient Derived Xenograft (PDX) Model Market highlight several key trends driving growth and innovation. The Patient Derived Xenograft (PDX) model market focuses on the use of tumor tissue from cancer patients implanted into immunodeficient mice, providing a more accurate representation of human tumors for drug development and research. These models are increasingly vital in oncology research due to their ability to mimic the genetic, histological, and behavioral traits of actual human cancers, making them more predictive of how treatments will perform in clinical trials. As personalized medicine and targeted therapies continue to evolve, the demand for PDX models has surged, becoming an essential tool for testing drug efficacy, studying treatment resistance, and identifying new biomarkers. This market is driven by the need for better preclinical models, the growing global cancer burden, and advancements in genomics, while the expansion of biobanks and improved model customization further fuel its growth.

Analyst view on the impacts of U.S. tariff rates on the Patient Derived Xenograft (PDX) Model Market

Despite these near-term obstacles, the long-term outlook for the PDX model market remains robust. This growth is driven by the increasing prevalence of cancer, the demand for personalized medicine, and advancements in cancer research methodologies. PDX models offer a more accurate representation of human tumor biology compared to traditional cell line models, making them invaluable in preclinical drug development. Furthermore, the integration of PDX models with genomic and proteomic technologies enhances their utility in biomarker discovery and therapeutic targeting. As regulatory frameworks evolve and technological innovations continue, the PDX model market is poised to play a pivotal role in the future of oncology research and personalized treatment strategies

Market Portfolio

Key Findings

• The PDX model market is primarily divided into two types: mice and rat models. Mice models dominate the market due to their biological similarity to human tumors, ease of manipulation, and the availability of immunodeficient strains. These factors contribute to the widespread use of mice in preclinical cancer research and drug development.

• Implantation methods for PDX models include subcutaneous and orthotopic techniques. Subcutaneous implantation involves placing tumor tissue under the skin of the host animal, offering simplicity and cost-effectiveness. Orthotopic implantation, where tumor tissue is placed in the original organ, provides a more accurate representation of human tumor behavior but is technically more challenging.

• The PDX model market is segmented based on tumor types, including respiratory and hematological cancers. Respiratory tumors, particularly lung cancer, are the fastest-growing segment due to the rising prevalence of lung cancer globally. Hematological tumors, though less prevalent, remain significant due to the complexity and heterogeneity of blood cancers.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as Personalized Medicine Demand, Enhanced Preclinical Predictability, Advancements in Tumor Biology Research, Increase in Oncology Research and Drug Development, Collaborations and Partnerships, Availability of Patient Tumor Samples, Regulatory Support and Guidelines, Potential for Reduced Animal Testing, Growing Focus on Precision Oncology, Advancements in Model Development and Characterization, Technological Developments, Humanized PDX Models, Collaborative Research Initiatives, Investment in Cancer Research, Focus on Immuno-Oncology have triggered the Patient Derived Xenograft (PDX) Model Market in the region.

Regional Analysis

North America to Dominate the Market

• North America holds a dominant position in the global PDX model market, driven by a combination of factors including a high prevalence of cancer, well-established research infrastructure, and significant investments in oncology research. The United States, in particular, leads the region, with a robust pharmaceutical and biotech industry that heavily relies on PDX models for preclinical testing and drug development. Government funding and private investments further bolster the adoption of these models, which offer more accurate predictions of therapeutic outcomes in human patients.

• Europe ranks as the second-largest market for PDX models, supported by strong government initiatives and research funding in oncology. Countries such as Germany, the United Kingdom, and France are leading contributors to the region’s growth, with a focus on precision medicine and personalized cancer treatments. The European Union’s regulatory framework encourages collaboration between pharmaceutical companies and academic institutions, fostering innovation and the application of PDX models in cancer research.

• The Asia-Pacific region is experiencing rapid growth in the PDX model market, driven by an increasing prevalence of cancer, particularly in countries like China, India, and Japan. Aging populations, lifestyle changes, and environmental factors contribute to the rising cancer burden. Advancements in healthcare infrastructure and a greater focus on tackling the growing cancer burden are propelling the demand for innovative research models like PDX. China, in particular, is investing heavily in immuno-oncology therapies, making PDX models essential tools in this research.

• Latin America is gradually emerging in the PDX model landscape, with countries like Brazil showing interest in developing advanced cancer research capabilities. Collaborations between local startups and international companies are fostering innovation in the region. While the market is still in its nascent stages, ongoing research and development efforts indicate a growing potential for PDX models in addressing cancer research challenges.

• The Middle East and Africa (MEA) region is witnessing steady growth in the PDX model market, primarily driven by increasing investments in cancer research and healthcare infrastructure in countries like the UAE and South Africa. The UAE’s focus on advanced cancer research and partnerships with international research organizations are boosting the adoption of PDX models for preclinical studies. However, the market's growth is tempered by challenges such as limited research funding and infrastructure in certain areas.

Competitive Landscape

• JSR Corporation
• Wuxi Apptec
• The Jackson Laboratory
• Charles River Laboratories International, Inc.
• Taconic Biosciences, Inc.
• Oncodesign Precision Medicine
• Inotiv, Inc.
• Pharmatest Services
• Hera BioLabs
• EPO Berlin-Buch GmbH
• Xentech
• Urosphere
• Altogen Labs
• Abnova Corporation
• Genesis Biotechnology Group
• Biocytogen Pharmaceuticals Co., Ltd.
• Creative Animodel
• BioDuro-Sundia
• Aragen Life Sciences
• Shanghai LIDE Biotech Co., Ltd.
• Certis Oncology Solutions
• InnoSer
• IVRS AB
• Beijing IDMO Co. Ltd.
• Shanghai Chempartner Co. Ltd.

Recent Developments

• In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, signed a global licensing agreement with ERS Genomics Limited. This agreement provided Crown Bioscience with unrestricted access to ERS's foundational CRISPR/Cas9 patent portfolio, allowing the company to leverage CRISPR/Cas9 for genetic editing worldwide. As part of the agreement, Crown Bioscience expanded its genetic manipulation capabilities and is investigating the potential of gene editing in three-dimensional models of patient-derived tumor organoids.

• In July 2022, GemPharmatech entered into a strategic licensing deal with Charles River Laboratories, Inc., granting the latter exclusive distribution rights for GemPharmatech's advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines across North America.

• In November 2021, Inotiv finalized the acquisition of Envigo RMS Holding Corp., a prominent global provider of research models and services.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Patient Derived Xenograft (PDX) Model Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope